(Bloomberg) -- Demand has grown so fervent for corporate bonds that investors are once again willing to finance big mergers and acquisitions — something they hesitated to do for much of last year.Most Read from BloombergBYD Unveils $233,450 EV Supercar to Rival Ferrari, LamborghiniBuffett Says ‘Eye-Popping’ Results Unlikely With Record CashTrump Advances 2024 Bid Besting Haley in Her Home StateFed-Favored Inflation Gauge Seen Rising Most in a YearRisk Models Behind World’s Best Hedge Fund Strate
European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.
(Bloomberg) -- Pharmaceutical giant AbbVie Inc. sold $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings. Most Read from BloombergNvidia Rises Most in About Nine Months as AI Drives SalesT-Bills Without Tax Bills? This Fund Says It Cracked the CodeStocks Rally as AI Craze Sweeps Across the World: Markets WrapAT&T Outage Triggered by Company Work on N